Begin a Phase 3 study for telisotuzumab vedotin
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 2 Feb 2022
- Due
- 30 Jun 2022
- Delivered
- May 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“a Phase 3 study is planned to begin in the first half of 2022.”
What we found
Evidence strength A What the grades mean
AbbVie initiated a Phase 3 clinical trial for telisotuzumab vedotin in May 2022, which is within the first half of 2022.
-
A AbbVie Inc. 10-Q filed 2022-08-04
“In May 2022, AbbVie initiated a Phase 3 clinical trial to evaluate Teliso-V versus docetaxel for the treatment of patients with previously treated c-Met overexpressing, epidermal growth factor receptor wild type, advanced/metastatic non-squamous non-small cell lung cancer.” ✓ confirmed on the page
Market reaction: the shares moved -0.3% against the S&P 500 over the three sessions around the disclosure (3 Aug 2022 to 8 Aug 2022). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Phase 3 study for telisotuzumab vedotin
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you AbbVie Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ABBV-004342 · Corrections policy